Good Efficacy of Artemether-Lumefantrine for Uncomplicated
Falciparum Malaria in Eastern Sumba, East Nusatenggara,
Indonesia by Sutanto, Inge et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Public Health Resources Public Health Resources
2012
Good Efficacy of Artemether-Lumefantrine for
Uncomplicated Falciparum Malaria in Eastern
Sumba, East Nusatenggara, Indonesia
Inge Sutanto
University of Indonesia, sutanto.inge@yahoo.com
Sri Suprianto
Communicable Diseases Control, Ministry of Health, Jakarta, Indonesia
Anri Widiaty
Waingapu Primary Health Center, East Sumba district, East Nusatenggara province, Indonesia
Waingapu Primary Health Center, East Sumba district, East Nusatenggara province, Indonesia;
Paul Ruckert
Deutsche Gesellschaft fûr Tehnische Zusammenarbeit (GTZ) Coordinator, GTZ. Health Programme & Health Services
Academy Park Road Chak Shehzad, Islamabad, Pakistan
See next page for additional authors
Follow this and additional works at: http://digitalcommons.unl.edu/publichealthresources
This Article is brought to you for free and open access by the Public Health Resources at DigitalCommons@University of Nebraska - Lincoln. It has
been accepted for inclusion in Public Health Resources by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Sutanto, Inge; Suprianto, Sri; Widiaty, Anri; Waingapu Primary Health Center, East Sumba district, East Nusatenggara province,
Indonesia;; Ruckert, Paul; von Bethmann, Alexander; de Monbrison, Frédérique; Picot, Stéphane; Laihad, Ferdinand; and Baird, J.
Kevin, "Good Efficacy of Artemether-Lumefantrine for Uncomplicated Falciparum Malaria in Eastern Sumba, East Nusatenggara,
Indonesia" (2012). Public Health Resources. 365.
http://digitalcommons.unl.edu/publichealthresources/365
Authors
Inge Sutanto; Sri Suprianto; Anri Widiaty; Waingapu Primary Health Center, East Sumba district, East
Nusatenggara province, Indonesia;; Paul Ruckert; Alexander von Bethmann; Frédérique de Monbrison;
Stéphane Picot; Ferdinand Laihad; and J. Kevin Baird
This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/
publichealthresources/365
187
ORIGINAL ARTICLE
Acta Medica Indonesiana - The Indonesian Journal of Internal Medicine
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ABSTRAK
Tujuan: untuk menilai keamanan dan efektifitas dari penggunaan kombinasi tetap artemeter-lumefantrine 
terhadap kegagalan terapi artesunat-amodiaquine lini pertama. Metode: studi ini merupakan penelitian terbuka 
tunggal tanpa kontrol. Kami menilai penggunaan terapi standar artemeter-lumefantrine terhadap 59 subyek 
dengan malaria tanpa komplikasi yang disebabkan oleh Plasmodium falciparum di pulau Sumba, Indonesia Timur. 
Tidak ada kegagalan terapi hingga hari ke-35. Seorang subjek memiliki parasitemia rekuren pada hari ke-42 
yang menunjukkan genotipe konsisten dengan rekrudesensi yang terjadi. Sehingga, efikasi terapi ini diperkirakan 
sebesar 98,3% (95% CI = 95%-100%). Analisis deskriptif dilakukan dengan menggunakan SPSS versi 12. 
Hasil: dua ratus tiga belas subyek dengan P. falciparum yang memenuhi kriteria inklusi dalam studi kemanjuran 
in vivo, 79 subyek diberi artemeter-lumefantrine dan 134 subyek diterapi dengan protokol lain menggunakan 
artesunat-amodiaquine atau sulfadoksin-pirimetamin. Di antara 79 subyek yang memenuhi kriteria, 59 subyek 
berhasil menyelesaikan pemeriksaan yang berlangsung selama 42 hari. Seperti yang diharapkan, nilai rerata 
PCT lebih lama dibandingkan nilai rerata FCT, yaitu masing-masing sebesar 1,34+0,67 (95% CI 1,21-1,47) 
dan 1,05+0,05 (95% CI 0,95-1,15) hari. Pada hari ke-3 pengobatan, baik demam maupun fase aseksual 
P. falciparum menghilang pada semua subyek. Pengamatan sampai hari ke-35 menunjukkan bahwa 59 subyek 
yang diobati dengan artemeter-lumefantrine ternyata sembuh. Kesimpulan: temuan dari studi tanpa kontrol ini 
menunjukkan keamanan dan efikasi yang baik artemeter-lumefantrine untuk pengobatan malaria falciparum 
tanpa komplikasi di Pulau Sumba dan Kepulauan Sunda Kecil di Indonesia.
Kata kunci: Artemisinin, artemeter-lumefantrin, Plasmodium falciparum, Indonesia.
ABSTRACT
Aim: to evaluate the safety and efficacy of a fixed combination of artemether-lumefantrine for likely use 
against failures of the artesunate-amodiaquine first line therapy. Methods: the study was an open label single 
arm uncontrolled trial. we evaluated the safety and efficacy of standard artemether-lumefantrine therapy in 
59 subjects with uncomplicated malaria caused by Plasmodium falciparum on the island of Sumba in eastern 
Indonesia. No treatment failures occurred up to day 35. One subject had recurrent parasitemia on day 42 that 
Acta Medica Indonesiana - The Indonesian Journal of Internal Medicine (2012) 44. 
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INTRODUCTION
In Indonesia chloroquine treatment failure 
during P. falciparum malaria ranges from 
25%--99% in almost every major island of this 
archipelago nation.1-3 Biomolecular studies of P. 
falciparum gene mutations linked to chloroquine 
resistance (pfcrt single nucleotide polmorphisms) 
tend to corroborate the in vivo findings from the 
field.4-5 
The Indonesian Ministry of Health finally 
replaced chloroquine as the first-line therapy for 
uncomplicated falciparum malaria in 2004, selecting 
the combination of artesunate-amodiaquine.6 The 
principal appeal to artesunate-amodiaquine as the 
drug of choice for the treatment of P. falciparum 
infection was the fact that amodiaquine was 
never before used in this country and its lower 
cost as compared to artemether-lumefantrine. 
Nevertheless, the high resistance rate of P. 
falciparum to chloroquine in almost all provinces 
in Indonesia, coupled with the possibility of cross 
resistance between chloroquine and amodiaquine 
have cast doubts on the sustainable efficacy of 
artesunate-amodiaquine.7-8 Due to low compliance 
of seven days quinine and doxycycline as the current 
second line, Indonesia might consider the adoption 
of artemether-lumefantrine as alternative.Therefore, 
this study explored the safety and efficacy of a fixed 
combination of artemether-lumefantrine for likely 
use against failures of the artesunate-amodiaquine 
first line therapy.
This study was conducted at the Waingapu 
Primary Health Center, Eastern Sumba district, 
Sumba Island in Eastern Nusatenggara province, 
from February to September 2004. Like other 
regions of Indonesia, Sumba has dry (May 
to November) and rainy (December to April) 
seasons. At the time of this study chloroquine and 
sulfadoxine-pyrimethamine were still the first- 
and the second-line therapies against falciparum 
malaria. However, in 2002, in vivo studies on 
these drugs in Eastern Nusatenggara, revealed 
that the failure rates of chloroquine were 65% 
and 69% on Western Sumba and Alor island, 
respectively, and 8.5% in Alor for sulfadoxine-
pyrimethamine.9-10 
METHODS
The study was an open labeled single arm 
uncontrolled trial. The inclusion criteria were 
in accordance with those recommended by the 
WHO.11 All subjects gave written informed 
consent. This research protocol was approved 
by the Committee of Medical Research Ethics of 
the Faculty of Medicine, University of Indonesia, 
Jakarta.
The eligible patients were then given 
Coartem® (Novartis) orally, which contains 20 
mg artemether and 120 mg lumefantrine in fixed 
combination, with the following dosage: body 
weight from 10 to14 kg: 2 x 1 tablet daily, BW 
from 15 to 24 kg: 2 x 2 tablets daily, BW from 
25 to 34 kg: 2 x 3 tablets daily, BW from 35 kg 
and above: 2 x 4 tablets daily. The drug was given 
for a total of 3 days. The morning dose and the 
evening dose were given in the Waingapu Health 
Centre under direct supervision. 
All subjects were followed up for 42 days 
and asked to return to the health centre on days 
1, 2, 3, 7, 14, 21, 28, 35, and 42. At each visit 
the axillary temperature was taken using a 
digital thermometer. Thick and thin blood films 
and blotting on Whatman filter paper no.1 for 
parasite genotyping were made by blood samples 
showed a genotype consistent with recrudescence. The efficacy of this therapy was thus estimated to be 98.3% 
(95% confidence interval=95%-100%). Descriptive analysis was done using the SPSS 12 computer software. 
Results: two hundred and thirteen P. falciparum patients met the inclusion criteria for in vivo efficacy study, 79 
were given artemether-lumefantrine and 134 were treated under another protocol with artesunate-amodiaquine or 
sulfadoxine-pyrimethamine. Among 79 eligible subjects, 59 successfully completed the 42-day test. As expected, the 
mean PCT was longer than the mean FCT, i.e. 1.34+0.67 (95% CI 1.21–1.47) and 1.05+0.05 (95% CI 0.95–1.15) 
days, respectively. On day 3 of treatment, both fever and asexual stage of P. falciparum disappeared in all subjects. 
Observation until Day 35 showed that all of the 59 subjects treated with artemether-lumefantrine were cured. 
Conclusion: the findings of this uncontrolled study suggest good safety and efficacy of artemether-lumefantrine 
for treatment of uncomplicated falciparum malaria on Sumba Island in the Lesser Sundas archipelago of eastern 
Indonesia. 
Key words: Artemisinin, artemether-lumefantrine, Plasmodium falciparum, Indonesia.
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obtained by finger prick. 
The observation of each patient ended if 
the treatment failed (becoming parasitemic), 
succeeded (remaining free of parasitemia up to 
day 42), or if lost to follow up, withdrawal from 
the study, or protocol violation. 
All adverse event data were collected from 
the patients in a yes-or-no form during their 
follow-up visits. If the adverse events started 
at day 0 and vanished concomitantly with the 
disappearance of fever and/or parasitemia, a 
disease-related causality was assumed. If the 
adverse event persisted despite disappearance 
of parasite and fever, a drug-related causality 
was explored. 
Parasite clearance time was determined 
from the first day of drug administration until 
its disappearance and persisted for 2 days. Fever 
clearance time was only evaluated in patients 
having fever on day 0 and measured at the point 
at which body temperature fell to <37.50C and the 
patient remained apyretic for 2 subsequent days. 
Blood samples for genetic analysis from 
patients were taken prior to treatment and at the 
time of treatment failure. This technique was 
applied to discriminate whether reapperance of 
parasitemia during follow up period originally 
from new infection or a recrudescence of old 
infection. Microscopic examination was not 
able to differentiate these two condiritons, 
but merozoite surface protein-2 genotyping 
discriminated recrudescence from re-infection. 
Real-time quantitative PCR, using LightCycler 
system (Roche Applied Science), was performed 
with fluorescent SYBR Green 1 dye binding 
specifically to double-stranded DNA.12 PCR 
product identity was assessed by the specific 
melting temperature obtained for each genotype 
and confirmed by gel electrophoresis migration.
Descriptive analysis was done using the 
SPSS 12 computer software. Only patients having 
taken 6 doses of drug and classified as “failed” 
or “successful” were included in the per-protocol 
analysis. 
RESULTS
Blood examination was done on 2,278 
patients who came to the Waingapu Primary 
Health Center suspected of having malaria. A 
total of 23% (525) had slide-proven malaria 
with P. falciparum (356) the dominant species 
followed by P. vivax (119), mixed infection of the 
two species (47), and P. malariae (3), respectively. 
Two hundred and thirteen P. falciparum 
patients met the inclusion criteria for in vivo 
efficacy study, 79 were given artemether-
lumefantrine and 134 were treated under 
another protocol with artesunate-amodiaquine 
or sulfadoxine-pyrimethamine (Sutanto et al, 
unpublished). Twenty out of 79 patients were then 
not included in per-protocol analysis for several 
reasons. Three were hospitalized on the first day 
of artemether-lumefantrine treatment. The reason 
of hospitalization of the 3 patients were vomiting, 
diarrhea and high fever (>390C). These symptoms 
were due to malaria disease, but were not related 
to the treatment. They were then given intravenous 
quinine and all were discharged from the hospital 
after 3 days. The other 12 were found to have 
P. vivax infection during the 42-day follow-up 
period. Four patients were lost to follow-up on 
day 28 (1 subject) or day 42 (3 subjects). One 
subject was exluded with evidence of P. falciparum 
reinfection as indicated by the PCR test showed 
3D7-type at admission and FC27-type on day 42, 
was therefore classified as having been reinfected. 
In summary, among 79 eligible subjects, 59 
successfully completed the 42-day test. 
As expected, the mean PCT was longer than 
the mean FCT, i.e. 1.34 + 0.67 (95% CI 1.21 – 
1.47) and 1.05 + 0.05 (95% CI 0.95 – 1.15) days, 
respectively. On Day 3 of treatment, both fever 
and asexual stage of P. falciparum disappeared 
in all subjects. 
Observation until Day 35 showed that all of the 
59 subjects treated with artemether-lumefantrine 
were cured. On day 42, however, parasitemia 
had reappeared in 1 subject. Genotyping analysis 
showed that one had identical 3D7-type alleles 
at admission and failure (d42), confirming 
recrudescence. Therefore, the corrected of cure 
rate on day 42 was 98.3% (58/59). The summary 
of recruitment patients until the outcomes of in 
vivo study is showed in Figure 1. 
Gametocytemia occurred in 18 (30.5%) 
subjects in this study. In 8 (13.6%) cases 
gametocytemia was identified prior to treatment, 
while in 10 (16.9%) it was found during the 
treatment period (six, three and one persons 
on days 1, 2 and 3, respectively). Thereafter, a 
consistent disappearance of gametocyte till day 
42 was observed in all cases. The mean length of 
the gametocytemia was 2.5 days (95% CI 1.59 – 
3.41, range 1 – 6 days). 
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The most frequent of physical complaints on 
day of recruitment were headache and nausea, 
which were 86.2% and 67.8%, respectively. 
Other complaints were far less common (Figure 
2). Complaint of headache became 16.9% on day-
7 and persisted to day 42 in 5% of these subjects. 
DISCUSSION
In the present study artemether-lumefantrine 
proved safe and highly efficacious in 59 residents 
of eastern Sumba Island presenting with 
uncomplicated falciparum malaria. Another study 
in southern Papua of Indonesia, an area with 
multidrug resistant P. falciparum also showed 
high cure rate (95.3%) of artemether-lumefantrine 
after PCR correction.13 The intensity of malaria 
transmission over the Indonesian archipelago 
varies widely among endemic areas, and pattern 
of drug resistance shift over both geographic 
area and time. Therefore, decision for treatment 
policy is more complex here than in other 
malaria countries. However, these two studies 
(Sumba and Papua) demonstrated good efficacy 
of the artemether-lumefantrine consistently. 
Other studies outside Indonesia also had shown 
that artemether-lumefantrine effective for P. 
falciparum in areas of low to high level of malaria 
transmission, in non immune or semi immune 
infected children, in addition to the multidrug 
resistant parasite, with efficacy of 93.6%, 93%, 
95%, 93.3% and 95.5%, respectively.14-17
Serious adverse events of the three hospitalized 
patients in this study could not only be attributed 
to the drug reactions itself, considering that 
headache and gastrointestinal disturbances were 
documented as major symptoms of patients on 
admission. All these patients were discharged 
from hospital without any sequelae. Therefore 
tolerance to artemether-lumefantrine in this study 
was deliberately good. 
Although this study showed good efficacy 
and tolerance of artemether-lumefantrine for 
P. falciparum cases, the high cost of the drug 
and its ineffectiveness to P. vivax as the other 
79
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Figure 1. P. falciparum enrolled cases in Eastern Sumba and its analyses to outcomes of in vivo artemether-lumefantrine 
efficacy study
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dominant species in Indonesia, limits artemether-
lumefantrine utilization as second line therapy 
to P. falciparum. The current second line for 
P. falciparum cases in Indonesia is seven 
days combination of quinine and doxycycline 
or tetracycline. The low compliance of this 
combination due to chinchonism makes it as 
unfavorable choice both for doctors and patients. 
Therefore, this study is important as preliminary 
data for searching a better second line therapy. 
CONCLUSION
The findings of this uncontrolled study 
suggest good safety and efficacy of artemether-
lumefantrine for treatment of uncomplicated 
falciparum malaria on Sumba Island in the Lesser 
Sundas archipelago of eastern Indonesia. A 
clinical trial of this combination against parasites 
that manage to survive treatment with artesunate-
amodiaquine is required to fully assess its value 
as a second line therapy for uncomplicated 
falciparum malaria. 
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Itching
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Gait disturbances
Blurred vision
Hearing disorder
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0 10 20 30 40 50 60 70 80 90 100
Percentage of clinical manifestation of adverse events on day of recruitment
Figure 2. Various clinical symptoms on admission of in vivo artemether-lumefantrine study in Eastern Sumba. Headache, 
nausea, abdominal pain, and diarrhea were the major symptoms 
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